{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T07:47:44Z","timestamp":1793346464272,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T00:00:00Z","timestamp":1554422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc.","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00125-019-4856-7","type":"journal-article","created":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T16:28:38Z","timestamp":1554481718000},"page":"948-958","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study"],"prefix":"10.1007","volume":"62","author":[{"given":"Robert S.","family":"Rosenson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha L.","family":"Daviglus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Handelsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Pozzilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold","family":"Bays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Monsalvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Elliott-Davey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ransi","family":"Somaratne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Reaven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,5]]},"reference":[{"key":"4856_CR1","doi-asserted-by":"crossref","first-page":"e007402","DOI":"10.1161\/JAHA.117.007402","volume":"6","author":"PR Lawler","year":"2017","unstructured":"Lawler PR, Akinkuolie AO, Harada P et al (2017) Residual risk of atherosclerotic cardiovascular events in relation to reductions in very-low-density lipoproteins. J Am Heart Assoc 6:e007402","journal-title":"J Am Heart Assoc"},{"issue":"14","key":"4856_CR2","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.jacc.2017.07.745","volume":"70","author":"DM Lloyd-Jones","year":"2017","unstructured":"Lloyd-Jones DM, Morris PB, Ballantyne CM et al (2017) 2017 focused update of the 2016 ACC Expert Consensus Decision Pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 70(14):1785\u20131822. https:\/\/doi.org\/10.1016\/j.jacc.2017.07.745","journal-title":"J Am Coll Cardiol"},{"issue":"9607","key":"4856_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","volume":"371","author":"PM Kearney","year":"2008","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaborators, Kearney PM, Blackwell L et al (2008) Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371(9607):117\u2013125. https:\/\/doi.org\/10.1016\/S0140-6736(08)60104-X","journal-title":"Lancet"},{"issue":"8","key":"4856_CR4","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.2337\/diacare.24.8.1422","volume":"24","author":"KJ Mukamal","year":"2001","unstructured":"Mukamal KJ, Nesto RW, Cohen MC et al (2001) Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction. Diabetes Care 24(8):1422\u20131427. https:\/\/doi.org\/10.2337\/diacare.24.8.1422","journal-title":"Diabetes Care"},{"issue":"15","key":"4856_CR5","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","volume":"137","author":"RP Giugliano","year":"2018","unstructured":"Giugliano RP, Cannon CP, Blazing MA et al (2018) Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation 137(15):1571\u20131582. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.030950","journal-title":"Circulation"},{"issue":"2","key":"4856_CR6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S2213-8587(16)30396-5","volume":"5","author":"AF Schmidt","year":"2017","unstructured":"Schmidt AF, Swerdlow DI, Holmes MV et al (2017) PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. Lancet Diabetes Endocrinol 5(2):97\u2013105. https:\/\/doi.org\/10.1016\/S2213-8587(16)30396-5","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"4856_CR7","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s10557-018-6816-8","volume":"32","author":"G Giustino","year":"2018","unstructured":"Giustino G, Colantonio LD, Brown TM et al (2018) Titration to high-intensity statin therapy following acute myocardial infarction in patients with and without diabetes mellitus. Cardiovasc Drugs Ther 32(5):453\u2013461. https:\/\/doi.org\/10.1007\/s10557-018-6816-8","journal-title":"Cardiovasc Drugs Ther"},{"issue":"12","key":"4856_CR8","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","volume":"5","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Leiter LA, Wiviott SD et al (2017) Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol 5(12):941\u2013950. https:\/\/doi.org\/10.1016\/S2213-8587(17)30313-3","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"4856_CR9","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s40262-017-0620-7","volume":"57","author":"S Kasichayanula","year":"2018","unstructured":"Kasichayanula S, Grover A, Emery MG et al (2018) Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor. Clin Pharmacokinet 57(7):769\u2013779. https:\/\/doi.org\/10.1007\/s40262-017-0620-7","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"4856_CR10","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1111\/j.1464-5491.2011.03360.x","volume":"28","author":"LA Leiter","year":"2011","unstructured":"Leiter LA, Lundman P, da Silva PM et al (2011) Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabet Med 28(11):1343\u20131351. https:\/\/doi.org\/10.1111\/j.1464-5491.2011.03360.x","journal-title":"Diabet Med"},{"issue":"10","key":"4856_CR11","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.jacc.2017.07.752","volume":"70","author":"RS Rosenson","year":"2017","unstructured":"Rosenson RS, Baker S, Banach M et al (2017) Optimizing cholesterol treatment in patients with muscle complaints. J Am Coll Cardiol 70(10):1290\u20131301. https:\/\/doi.org\/10.1016\/j.jacc.2017.07.752","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"4856_CR12","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","volume":"63","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH et al (2014) 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63(25):2889\u20132934. https:\/\/doi.org\/10.1016\/j.jacc.2013.11.002","journal-title":"J Am Coll Cardiol"},{"issue":"Supplement 2","key":"4856_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP171764.APPGL","volume":"23","author":"Paul S. Jellinger","year":"2017","unstructured":"Jellinger PS, Handelsman Y, Rosenblit PD et al (2017) American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. Endocr Pract 23(Suppl 2):1\u201387. https:\/\/doi.org\/10.4158\/EP171764.APPGL","journal-title":"Endocrine Practice"},{"issue":"Suppl 1","key":"4856_CR14","doi-asserted-by":"publisher","first-page":"S152","DOI":"10.2337\/dc18-S015","volume":"41","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association (2018) 15. Diabetes Advocacy: Standards of Medical Care in Diabetes-2018. Diabetes Care 41(Suppl 1):S152\u2013S153. https:\/\/doi.org\/10.2337\/dc18-S015","journal-title":"Diabetes Care"},{"issue":"18","key":"4856_CR15","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC et al (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376(18):1713\u20131722. https:\/\/doi.org\/10.1056\/NEJMoa1615664","journal-title":"N Engl J Med"},{"issue":"7","key":"4856_CR16","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1161\/ATVBAHA.118.310882","volume":"38","author":"DC Chan","year":"2018","unstructured":"Chan DC, Watts GF, Somaratne R, Wasserman SM, Scott R, Barrett PHR (2018) Comparative effects of PCSK9 (proprotein convertase subtilisin\/kexin type 9) and statins on postprandial triglyceride-rich lipoprotein metabolism. Arterioscler Thromb Vasc Biol 38(7):1644\u20131655. https:\/\/doi.org\/10.1161\/ATVBAHA.118.310882","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"23","key":"4856_CR17","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","volume":"63","author":"MJ Koren","year":"2014","unstructured":"Koren MJ, Lundqvist P, Bolognese M et al (2014) Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol 63(23):2531\u20132540. https:\/\/doi.org\/10.1016\/j.jacc.2014.03.018","journal-title":"J Am Coll Cardiol"},{"issue":"9858","key":"4856_CR18","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","volume":"380","author":"MJ Koren","year":"2012","unstructured":"Koren MJ, Scott R, Kim JB et al (2012) Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 380(9858):1995\u20132006. https:\/\/doi.org\/10.1016\/S0140-6736(12)61771-1","journal-title":"Lancet"},{"issue":"1","key":"4856_CR19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/dme.13450","volume":"35","author":"LA Leiter","year":"2018","unstructured":"Leiter LA, M\u00fcller-Wieland D, Baccara-Dinet MT, Letierce A, Samuel R, Cariou B (2018) Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials. Diabet Med 35(1):121\u2013130. https:\/\/doi.org\/10.1111\/dme.13450","journal-title":"Diabet Med"},{"issue":"39","key":"4856_CR20","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1093\/eurheartj\/ehw292","volume":"37","author":"HM Colhoun","year":"2016","unstructured":"Colhoun HM, Ginsberg HN, Robinson JG et al (2016) No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY phase 3 studies. Eur Heart J 37(39):2981\u20132989. https:\/\/doi.org\/10.1093\/eurheartj\/ehw292","journal-title":"Eur Heart J"},{"issue":"12","key":"4856_CR21","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1111\/dom.13114","volume":"19","author":"LA Leiter","year":"2017","unstructured":"Leiter LA, Cariou B, M\u00fcller-Wieland D et al (2017) Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: the ODYSSEY DM-INSULIN randomized trial. Diabetes Obes Metab 19(12):1781\u20131792. https:\/\/doi.org\/10.1111\/dom.13114","journal-title":"Diabetes Obes Metab"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-019-4856-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-019-4856-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-019-4856-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T10:30:10Z","timestamp":1663237810000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-019-4856-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,5]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["4856"],"URL":"https:\/\/doi.org\/10.1007\/s00125-019-4856-7","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,5]]},"assertion":[{"value":"20 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RSR reports: research grants to his institution from Akcea, Amgen, AstraZeneca, CVS Caremark, The Medicines Company, Regeneron and Sanofi; advisory boards for Amgen, Regeneron and Sanofi; honoraria from Akcea, Kowa and Pfizer; stock holdings in MediMergent; and royalties from UpToDate Inc. Neither HB nor his affiliated research centre own pharmaceutical stocks or patents. In the past 12\u00a0months, HB\u2019s research site has received research grants from Amarin, Amgen, Alere, Allergan, Arisaph, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Catabasis, Dr. Reddy\u2019s, Eisai, Elcelyx, Lilly, Esperion, Ferrer\/Chiltern, Gemphire, Gilead, GlaxoSmithKline, iSpecimen, Janssen, Johnson & Johnson, Kowa, Merck, Nektar, Nichi-Iko, Novartis, Novo Nordisk, Pfizer, Regeneron, Sanofi, Selecta, Takeda and TIMI. In the past 12\u00a0months, HB has served as a consultant\/advisor for Alnylam, Akcea, Amgen, AstraZeneca, Eisai, Lilly, Esperion, Ionis (ISIS), Janssen, Johnson & Johnson, Kowa, Merck, Novartis, ProSciento, Regeneron and Sanofi. In the past 12\u00a0months, HB has served as a speaker for Amarin, Amgen, Eisai, Kowa, Orexigen, Regeneron and Sanofi. MLD is a member of the Repatha LCM Scientific Advisory Board. MLM is currently employed by Amgen Inc. and holds Amgen stock\/stock options. ME-D is currently employed by Amgen Ltd. and holds Amgen stock\/stock options. PP reports: advisory board\/lecture honoraria from Lilly, Sanofi and MSD; participation in clinical trials for Lilly, Janssen, Lexicon, AstraZeneca, MSD, Boehringer Ingelheim and GlaxoSmithKline; and research funding or grants from Lilly, MSD, Sanofi, AstraZeneca, Lexicon and Janssen. RS was previously employed by Amgen, holds Amgen stock\/stock options and is an inventor on at least one pending patent application owned by Amgen Inc. related to evolocumab. YH reports research grants and consultant and speaker honoraria from Aegerion, Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Boehringer Ingelheim\u2013Lilly, Eisai, Gan & Lee, Grifols, Hanmi, Intarcia, Janssen, Lexicon, Lilly, Merck, Merck-Pfizer, Novo Nordisk, Regeneron and Sanofi. PR reports: research grants from Novo Nordisk and (in the past 12\u00a0months) grants from Bristol-Myers Squibb; and consulting with Sanofi.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Duality of interest"}}]}}